Biotechnology
Medical
Biopharmaceutical
Alnylam Pharmaceuticals
$84.529876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$84.52
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$6.22 (-6.85%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell ALNY and other stocks, options, ETFs, and crypto commission-free!
About
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. Read More The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Employees
1,065
Headquarters
Cambridge, Massachusetts
Founded
2002
Market Cap
9.18B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
903.97K
High Today
$90.45
Low Today
$84.31
Open Price
$90.07
Volume
296.63K
52 Week High
$143.59
52 Week Low
$60.27
Collections
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
Health
Therapy
Technology
US
News
Yahoo FinanceMar 18
Alnylam's (ALNY) Impressive Pipeline Drives Share Price
Share price of Alnylam Pharmaceuticals Inc. ALNY increased 25.4% year to date compared with the industry’s growth of 15.9%. Alnylam is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference (RNAi). In August 2018, the company’s lead drug, Onpattro (patisiran) received regulatory approvals in the United States and Europe for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. Onpattro is the first and only FDA-ap...
Seeking AlphaMar 14
Alnylam Is A Step Closer To Its Second Approved Drug
Alnylam shares remain undervalued, and the company will likely have two approved drugs on the market in 2020 and four or five in 2021. Kidney and liver side effects are not trivial, but need to be considered relative to the seriousness of porphyria and the lack of discontinuations in the study. The last twelve months haven’t been particularly good in terms of market performance for Alnylam Pharmaceuticals (ALNY), and that hasn’t really changed much over the last three months either, as the shares continue...
Yahoo FinanceMar 12
See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc NASDAQ/NGS:ALNY View full report here! Summary Bearish sentiment is low Bearish sentiment Short interest | Positive Short interest is low for ALNY with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flow ETF/Index ownership | Neutral ETF activity is neutral. ETFs that hold ALNY had ne...
Price Paid on Robinhood
9% Lower
Right Now
52 Week Low
$60.27
Average Price Paid
$92.72
52 Week High
$143.59
Earnings
-$2.28
-$1.87
-$1.47
-$1.06
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 2, After Hours